Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04241796 · ClinicalTrials.gov registry record · NA
Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
A NA study, sponsored by GRAIL.
- Completed
- Registry status
- NA
- Development phase
- 6,662
- Enrollment target
NCT04241796: Completed NA study, sponsored by GRAIL.
NCT04241796 is a NA study that has completed, run by GRAIL. The registered enrollment target is 6,662 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (375% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04241796, a NA study, has completed, sponsored by GRAIL.
- COMPLETED
- Registry status
- NA
- Development phase
- 6,662 participants
- Enrollment target
Study Summary
PATHFINDER is a prospective, multi-center study in which approximately 6,200 participants will be enrolled. An investigational multi-cancer early detection test, developed by GRAIL, will be ordered by and results returned to a study investigator. In cases with a "signal detected" test result (with a predicted or indeterminate tissue of origin (TOO)), the diagnostic work-up will not be dictated by the protocol, but will instead be coordinated by the ordering and treating medical team at the enrolling sites based on the participant's clinical condition, recommendations by each institution's clinical practices, and in consultation with the study investigator and interdisciplinary care team, as necessary. Additionally, proposed clinical care pathways, developed based on a review of guidelines from the National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR) and other professional organizations, should be referenced by the medical team to determine the diagnostic work-up. The number and types of diagnostic procedures required to achieve diagnostic resolution will be assessed. Performance of multi-cancer early detection test will be evaluated. Additionally, participant-reported outcomes will be collected at several time points to assess participants' perceptions about the multi-cancer early detection test. Participants will be followed for approximately 12 months from the time of enrollment. Cancer status will also be assessed at the 12 month time point.
Interventions
- DEVICE Multi-Cancer Early Detection Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,662 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2022-01-05 |
| Phase | NA |
What the finished NCT04241796 record still lists
NCT04241796 is an interventional study that assigns participants to a tested intervention. Its 6,662 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (375% higher).
The record links to 0 conditions, and to 1 intervention - of which Multi-Cancer Early Detection Test is the first listed.
NCT04241796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04241796 about?
NCT04241796 is a clinical study titled "Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice". PATHFINDER is a prospective, multi-center study in which approximately 6,200 participants will be enrolled. An investigational multi-cancer early detection test, developed by GRAIL, will be ordered by and results returned to a study investigator. In cases with a "signal detected" test result (with a...
What is the current status of trial NCT04241796?
This trial is currently completed. It is a NA study. The enrollment target is 6,662 participants. The study started on 2019-12-12. Estimated completion is 2022-01-05.
What interventions are being tested in trial NCT04241796?
The interventions under investigation include: Multi-Cancer Early Detection Test (DEVICE).
Who is sponsoring clinical trial NCT04241796?
This trial is sponsored by GRAIL, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04241796's enrollment target sits among peer trials
6,662 21st of 2000 higher than 1,980 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05121324 · 6,700 participants · Phase 3
Pediatric Dose Optimization for Seizures in Emergency Medical Services
- NCT06272045 · 6,618 participants · NA
Early Intervention to Promote Cardiovascular Health of Mothers and Children
- NCT05143697 · 6,600 participants · NA
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
- NCT05515224 · 6,600 participants · NA
5-Cog 2.0: A Pragmatic Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI